Boston Scientific to Cut Jobs in $800M Restructuring, Eyes $500M Annual Savings
BSX is trading near its 52-week low of $42.2 (7.2% above the low).
Summary
Boston Scientific is launching a global restructuring that will include layoffs, with pre-tax charges of $700M–$800M, of which $275M–$300M is for termination benefits. The plan aims to deliver $500M in annual pre-tax expense savings and will be substantially complete by end of 2029. This follows the 8-K filed earlier today and comes amid a period of active capital deployment, including a $2B ASR and a $1.5B strategic investment in MiRus. The restructuring signals a focus on operational efficiency, but the multi-year timeline and lack of headcount specifics temper immediate impact. Watch for further details on the scope of layoffs and any updates on the Watchman device slowdown noted in May.
At the time of this announcement, BSX was trading at $45.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $67.6B. The 52-week trading range was $42.20 to $109.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.